Sugi Predict

Sugi Predict / Targets / CHRNB4

CHRNB4

Neuronal acetylcholine receptor subunit beta- · P30926 · CHRNB4 on Sugi Atlas →

126,892 patent compounds predicted against CHRNB4, 58,175 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Radafaxine Radafaxine (SCHEMBL48964) 1.00 20/20
SCHEMBL80066 SCHEMBL80066 0.65 14/20
Bromide Bromide (SCHEMBL69311) 0.62 13/20
Gallamine Gallamine (SCHEMBL249090) 0.58 12/20
SCHEMBL206365 SCHEMBL206365 0.50 12/20
SCHEMBL80814 SCHEMBL80814 0.72 11/20
Stilonium Stilonium (SCHEMBL26104) 1.00 10/20
Stilonium Stilonium (SCHEMBL26105) 1.00 10/20
SCHEMBL165812 SCHEMBL165812 0.87 10/20
Cytisinicline Cytisinicline (SCHEMBL161398) 1.00 9/20
SCHEMBL80826 SCHEMBL80826 0.58 9/20
SCHEMBL201988 SCHEMBL201988 0.56 9/20
SCHEMBL232661 SCHEMBL232661 0.56 9/20
SCHEMBL81218 SCHEMBL81218 0.53 9/20
SCHEMBL81293 SCHEMBL81293 0.51 9/20
Fumaric Acid Fumaric Acid (SCHEMBL237911) 0.80 7/20
Fumaric Acid Fumaric Acid (SCHEMBL237912) 0.80 7/20
SCHEMBL247201 SCHEMBL247201 0.54 7/20
SCHEMBL218547 SCHEMBL218547 0.44 7/20
SCHEMBL159158 SCHEMBL159158 0.64 6/20

Clinical trials — most relevant to CHRNB4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
Dexmedetomidine Effect on Delirium of Elderly Patients PHASE4UNKNOWN
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail PHASE1/PHASE2COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition PHASE2RECRUITING
Nicotinic Receptor Augmentation of SSRI Antidepressants PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
Gene Therapy for Alzheimer's Disease Clinical Trial PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
Brain Imaging in Alzheimer's Disease nanCOMPLETED
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia nanCOMPLETED
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia nanCOMPLETED
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. nanRECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease nanCOMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
The Genetic Characterization of Dementia nanCOMPLETED
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation nanRECRUITING
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNB4 binder may also engage these)

ProteinNameSimilarity
Q8SPU6 — 1.000 Q8SPU6 →
P09484 — 0.999 P09484 →
P12392 — 0.997 P12392 →
P19370 — 0.997 P19370 →
Q8R493 — 0.996 Q8R493 →
CHRNB2 Neuronal acetylcholine receptor subunit beta-2 0.994 landscape →
Q9ERK7 — 0.993 Q9ERK7 →
Q8R4G9 — 0.993 Q8R4G9 →
CHRNA6 Neuronal acetylcholine receptor subunit alpha 0.993 landscape →
Q07263 — 0.992 Q07263 →
P26153 — 0.992 P26153 →
Q5IS51 — 0.992 Q5IS51 →
Q9N587 — 0.992 Q9N587 →
P04757 — 0.992 P04757 →
P12390 — 0.991 P12390 →
P20420 — 0.991 P20420 →
CHRNA3 Neuronal acetylcholine receptor subunit alpha-3 0.991 landscape →
P02712 — 0.990 P02712 →
P04755 — 0.990 P04755 →
Q91X60 — 0.989 Q91X60 →
P25162 — 0.989 P25162 →
CHRNA1 Acetylcholine receptor subunit alpha 0.989 landscape →
P02710 — 0.988 P02710 →
P26152 — 0.988 P26152 →
Q2MKA5 — 0.987 Q2MKA5 →
P48181 — 0.987 P48181 →
A8WQK3 — 0.987 A8WQK3 →
P43679 — 0.987 P43679 →
P49579 — 0.987 P49579 →
P91766 — 0.986 P91766 →